NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis $7.45 -0.19 (-2.49%) As of 04/7/2025 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Daxor Stock (NASDAQ:DXR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daxor alerts:Sign Up Key Stats Today's Range$7.23▼$7.5650-Day Range$7.05▼$8.3952-Week Range$6.55▼$10.00Volume3,899 shsAverage Volume7,252 shsMarket Capitalization$36.04 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingBuy Company OverviewDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Read More… Remove Ads Daxor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreDXR MarketRank™: Daxor scored higher than 63% of companies evaluated by MarketBeat, and ranked 323rd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDaxor has only been the subject of 1 research reports in the past 90 days.Read more about Daxor's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.64% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daxor has recently increased by 12.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldDaxor does not currently pay a dividend.Dividend GrowthDaxor does not have a long track record of dividend growth.Read more about Daxor's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.64% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daxor has recently increased by 12.17%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Daxor this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Daxor to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Daxor insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,082.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders59.00% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.34% of the stock of Daxor is held by institutions.Read more about Daxor's insider trading history. Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address DXR Stock News HeadlinesDaxor Co. (NASDAQ:DXR) CEO Buys $25,804.80 in StockMarch 12, 2025 | insidertrades.comDaxor announces new data from Duke University on BVA at ACCApril 2, 2025 | markets.businessinsider.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 8, 2025 | Altimetry (Ad)Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and ExpoApril 2, 2025 | globenewswire.comDaxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare NetworksMarch 28, 2025 | globenewswire.comDaxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comEarnings call transcript: Daxor Q4 2024 sees 116.5% revenue growthMarch 8, 2025 | investing.comDaxor Corporation (DXR) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comSee More Headlines DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed this year? Daxor's stock was trading at $7.69 at the beginning of 2025. Since then, DXR shares have decreased by 3.1% and is now trading at $7.45. View the best growth stocks for 2025 here. How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and Company Calendar Today4/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DXR CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+235.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.13 million Price / Sales16.91 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,837,000Free Float1,983,000Market Cap$36.04 million OptionableNot Optionable Beta-0.06 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DXR) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk Demands Fort Knox AuditWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.